


=>
Uploading C:\STNEXP4\QUERIES\347a.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 11:22:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

L3 0 L2

=> s l1 full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 11:23:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

L4 3 SEA SSS FUL L1

L5 2 L4

=> d 1-2 ibib abs hitstr

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:390210 CAPLUS

DOCUMENT NUMBER: 140:406739

TITLE: Preparation of quaternary ammonium compounds, in particular butynylammonium glycolates, as muscarinic receptor antagonists

INVENTOR(S): Slatter, John Gregory

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 15 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039763	A1	20040513	WO 2003-IB4593	20031017
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD</p> <p>RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG</p>				
US 2004116519	A1	20040617	US 2003-688347	20031017
<p>PRIORITY APPLN. INFO.: US 2002-421982P P 20021029</p>				
<p>OTHER SOURCE(S): MARPAT 140:406739</p>				

GI



I

AB Title compds. I•X- [wherein R1 = (un)substituted alkyl, CH2-alkenyl,

CH₂-alkynyl; X = anion of a pharmaceutically acceptable acid such as tartaric, HCL, HBr, HI, H₂SO₄, H₃PO₄, HNO₃, citric, methanesulfonic, benzoic, etc.; and any of their stereoisomers] were prepared as muscarinic receptor antagonists for treating asthma, chronic obstructive pulmonary disorder, allergic rhinitis, and infectious rhinitis. For example, II•I- (I•X-, R1 = Me, X = I-) was prepared by alkylation of the corresponding amine with Me iodide in toluene/acetonitrile overnight at 20-25°. I exhibited prolonged efficacy as an antimuscarinic agent (no data).


IT 688364-67-2P, 4-(Diethylmethylammonium)-2-butynyl- α -phenylcyclohexane glycolate iodide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antimuscarinic agent; preparation of quaternary ammonium compds., in particular butynylammonium glycolates, as muscarinic receptor antagonists)

RN 688364-67-2 CAPLUS

CN 2-Butyn-1-aminium, 4-[(cyclohexylhydroxyphenylacetyl)oxy]-N,N-diethyl-N-methyl-, iodide (9CI) (CA INDEX NAME)



● I⁻

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:521917 CAPLUS

DOCUMENT NUMBER: 135:111979

TITLE: Oxybutynin compositions for the management of incontinence

INVENTOR(S): Guittard, George V.; Jao, Francisco; Marks, Susan M.; Kidney, David J.; Gumucio, Fernando E.

PATENT ASSIGNEE(S): Alza Corp., USA

SOURCE: U.S., 13 pp., Cont.-in-part of U.S. 5,912,268.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6262115	B1	20010717	US 1999-280309	19990329
US 5674895	A	19971007	US 1995-445849	19950522
US 5840754	A	19981124	US 1996-706576	19960905
US 5912268	A	19990615	US 1997-806773	19970226
AU 9912563	A1	20000426	AU 1999-12563	19981007
AU 9890522	A1	19990114	AU 1998-90522	19981103
AU 718849	B2	20000420		
US 2001005728	A1	20010628	US 2001-785805	20010216
US 2004043943	A1	20040304	US 2003-645715	20030820
PRIORITY APPLN. INFO.:			US 1995-445849	A2 19950522
			US 1996-706576	A2 19960905
			US 1997-806773	A2 19970226
			AU 1996-56392	A3 19960508
			WO 1998-IB1982	A 19981007

US 1999-280309 A1 19990329

US 2001-785805 A1 20010216

AB A dosage form comprises oxybutynin alone/or accompanied by another drug is useful for the management of incontinence and other therapy. Thus, a therapeutic composition (in a granule form) comprised oxybutynin-HCl 3.4, 76 wt PEG (MW 200,000) 76, hydroxypropyl Me cellulose of (MW 9200) 5, NaCl 15, and Mg stearate 0.6% by weight. The therapeutic composition can be administered for its intended oxybutynin therapy, the management of overactive bladder.

IT 350229-43-5

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oxybutynin comps: for management of incontinence)


RN 350229-43-5 CAPLUS

CN 2-Butyn-1-aminium, 4-[(cyclohexylhydroxyphenylacetyl)oxy]-N,N-diethyl-N-methyl-, nitrate (9CI) (CA INDEX NAME)

CM 1

CRN 350229-42-4


CMF C23 H34 N O3



CM 2

CRN 14797-55-8

CMF N O3



REFERENCE COUNT:


48

THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s oxybutynin/cn
L5 1 OXYBUTYNIN/CN

=> d

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 5633-20-5 REGISTRY
CN Benzeneacetic acid, α -cyclohexyl- α -hydroxy-,
4-(diethylamino)-2-butynyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Butyn-1-ol, 4-(diethylamino)-, α -phenylcyclohexaneglycolate
(ester)
CN Cyclohexaneglycolic acid, α -phenyl-, 4-(diethylamino)-2-butynyl
ester (8CI)
OTHER NAMES:
CN (\pm)-Oxybutynin
CN (RS)-Oxybutynin
CN 4-Diethylamino-2-butynyl α -phenylcyclohexaneglycolate
CN Ditropan
CN **Oxybutynin**
CN Oxytrol
FS 3D CONCORD
DR 119579-36-1
MF C22 H31 N O3
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS,
BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNB, CEN, CHEMCATS, CIN,
CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS,
IPA, MEDLINE, MRCK*, PHAR, PROMT, PS, RTECS*, SPECINFO, TOXCENTER, USAN,
USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO
DT.CA Caplus document type: Conference; Dissertation; Journal; Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or
reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
study); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP
(Properties); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological
study); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

341 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
344 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

=>